Andere talen Huadong Medicine Co., Ltd

Aandelen

000963

CNE0000011S1

slotkoers Shenzhen S.E. Andere beurzen 00:00:00 17-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
30,05 ^CNY	+1,90%		+1,11%	-27,52%

03:05	Huadong Medicine's winst in 2023 springt 14% omhoog	MT
03/04	China's eerste biosimilar Ozempic medicijn vraagt goedkeuring aan	RE

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Huadong Medicine's 2023 Profit Jumps 14%	03:05
El primer medicamento chino bioequivalente a Ozempic solicita su aprobación	03/04
China's first biosimilar Ozempic drug applies for approval	03/04
Huadong Medicine to Build 2 Billion Yuan Biopharma Innovation Center	09/02
Huadong Medicine to Invest 2 Billion Yuan in Biopharma Innovation Center	09/02
Huadong Medicine's 2023 Profit to Climb Up to 14.5%	01/02
Huadong Medicine Eyes Exclusive Marketing Rights for Cancer Drug Senaparib in China for 290 Million Yuan	21/12
Huadong Medicine's Unit Gains Chinese Drug Regulator's Nod to Trial Sirolimus Oral Solution	06/12
Chongqing Yuyan Pharmaceutical Co., Ltd. announced that it has received CNY 300 million in funding from Huadong Medicine Co., Ltd, Hangzhou State Capital Investment And Operations Co., Ltd., Hangzhou Gongshu State Investment Industry Development Co., Ltd.	15/11
Huadong Medicine's Unit, Partners to Invest in Pharmaceutical Firm	14/11
Huadong Medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	24-10-23
Huadong Medicine's Unit Gets Nod to Test Weight Management Drug; Shares Up 3%	15-09-23
MC2 Therapeutics and Huadong Announce License, Development and Commercialization Agreement for Wynzora Cream in Greater China	01-09-23
Huadong Medicine Enters Exclusive Licensing Agreement with Denmark’s MC2	01-09-23
CARsgen Announced 2023 Interim Results	23-08-23
Huadong Medicine’s H1 Profit Rises 7%; EPS, Revenue Miss Forecasts	16-08-23
Huadong Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	15-08-23
Huadong Medicine Buys Rights to US Skincare Drug For $100 Million	14-08-23
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia	11-08-23
Arcutis Authorizes Huadong Medicine Unit to Manufacture, Commercialize Topical Roflumilast in China, Southeast Asia	10-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Huadong Medicine Co., Ltd

Aandelen

000963

CNE0000011S1

Andere talen

Filters